Current role of therapy with amphotericin b

Clinical Infectious Diseases

Volumn 14, Issue , 1992, Pages S154-S160

  Meyer, Richard D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; RIFAMPICIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDIASIS; CONFERENCE PAPER; CRYPTOCOCCOSIS; DRUG COMBINATION; DRUG EFFICACY; DRUG RESPONSE; FEVER; HISTOPLASMOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SYSTEMIC MYCOSIS;

AMPHOTERICIN B; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG RESISTANCE, MICROBIAL; HUMAN; INFUSIONS, INTRAVENOUS; MYCOSES;

EID: 85047698189     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/14.Supplement_1.S154     Document Type: Article

References (63)

1. Eickhoff TC, Young LS. Gaps in therapy for infectious diseases: conference summary. J Infect Dis 1982;145:407-12.
2. Armstrong D. Problems in management of opportunistic fungal diseases. Rev Infect Dis 1989; 1 1 (suppl 7):S 1591-9.
3. Hoeprich PD. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 1992;14(suppl 1):S114-9.
4. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
5. Rinaldi MG. Emerging opportunists. Infect Dis Clin North Am 1989;3:65-76.
6. Holmberg K, Meyer RD, eds. Diagnosis and therapy of systemic fungal infections. New York: Raven Press, 1989:1-210.
7. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11:379-90.
8. Anaissie E, Bodey GP, Kantrarjian H, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989; 11:369-78.
9. Martino P, Venditti M, Micozzi A, et al. Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev Infect Dis 1990;12:570-82.
10. Walsh TJ, Melcher GP, Rinaldi MG, Callender D, Rubin M, Pizzo PA. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990;28:1616-22.
11. Salkin IF, McGinnis MR, Dykstra MJ, Rinaldi MG. Scedosporium in-flalum, an emerging pathogen. J Clin Microbiol 1988;26:498-503.
12. Drutz DJ, Lehrer RI. Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci 1978;276:77-92.
13. Pappagianis D, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 1979;16:123-6.
14. Dick JD, Rosengard BR, Merz WG, Stuart RK, Hutchins GM, Sarai R. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med 1985;102:67-8.
15. Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C. Mycoses caused by Candida lusitaniae. Rev Infect Dis 1987;9:1006-12.
16. Walsh TJ, Salkin IF, Dixon DM, Hurd NJ. Clinical, microbiological, and experimental animal studies of Candida lipolytica. J Clin Microbiol 1989;27:927-31.
17. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-32.
18. Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol 1989;27:236-40.
19. Nielsen H, Stenderup J, Bruun B, Ladefoged J. Candida norvegensis peritonitis and invasive disease in a patient on continuous ambulatory peritoneal dialysis. J Clin Microbiol 1990;28:1664-5.
20. Seidenfeld SM, Cooper BH, Smith JW, Luby JP, Mackowiak PA. Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. J Infect Dis 1983; 147:116-9.
21. Chia JKS, McManus EJ. In vitro tumor necrosis factor induction assay for analysis offebrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 1990;34:906-8.
22. Oldfield EC III, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother 1990;34:1402-6.
23. Roncoroni AJ, Corrado C, Besuschio S, Pavlovsky S, Narvaiz M. Bronchiolitis obliterans possibly associated with amphotericin B (letter). J Infect Dis 1990; 161:589.
24. Branch RA, Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
25. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for amphotericin b-associated nephrotoxicity. Am J Med 1989;87:547-52.
26. Wasan KM, Vadiel KL, Lopez-Berestein G, Verani RR, Luke DR. Pentoxifylline in amphotericin B toxicity rat model. Antimicrob Agents Chemother 1990;34:241-4.
27. Galgiani JN. Antifungal susceptibility tests. Antimicrob Agents Chemother 1987;31:1867-70.
28. Rinaldi MG. Laboratory evaluation of antifungal agents: a brief overview. Clin Infect Dis 1992;14(suppl 1):S 130-3.
29. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990;34:183-8.
30. Wong PK, Ching WTW, Kwon-Chung KJ, Meyer RD. Disseminated Phialophora parasitica infection in humans: case report and review. Rev Infect Dis 1989; 11:770-5.
31. Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980;302:145-55.
32. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;302:126-31.
33. Fujita NK, Edwards JE Jr. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob Agents Chemother 1981; 19:196-8.
34. Hughes CE, Harris J, Moody JA, Peterson LR, Gerding DN. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob Agents Chemother 1984;25:560-2.
35. Christenson JC, Itamar S, Welch DF, Guruswamy A, Marks MI. Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob Agents Chemother 1987;31:1775-8.
36. Naficy AB, Murray HW. Isolated meningitis caused by Blastoschizomyces capitatus [letter], J Infect Dis 1990;161:1041-2.
37. Medoff G. Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. Rev Infect Dis 1987;9:403-7.
38. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646-55.
39. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Rev Infect Dis 1990;12:1147-1201.
40. Soutar RL. Fluconazole or amphotericin for candidosis in neutropenic patients [letter]. Lancet 1991;337:181.
41. Case CP, MacGowan AP, Brown NM, Reeves DS, Whitehead P, Felmingham D. Prophylactic oral fluconazole and Candida fungaemia [letter]. Lancet 1991;337:790.
42. Mcllroy MA. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhilitis [letter], J Infect Dis 1991;163:420-1.
43. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88-100.
44. Bodey GP, Anaissie EJ. Chronic systemic candidiasis [editorial], Eur J Clin Microbiol Infect Dis 1989;8:855-7.
45. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989;149:2533-6.
46. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14(suppl 1):S43-53.
47. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;337:334-41.
48. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990; 113:183-7.
49. White M, Blevins A, Armstrong D. Cryptococcosis in the immunocompromised host: outcome in HIV-infection vs lymphoma, [abstract no 92] In: Program and abstracts of the International Symposium on Infections in the Immunocompromised Host. Peebles, Scotland: Immunocompromised Host Society, 1990.
50. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321:794-9.
51. Dismukes WE. Cryptococcal meningitis in patients with AIDS [editorial], J Infect Dis 1988;157:624-8.
52. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JR. Cryptococcal disease in patients with acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med 1986;1043:234-40.
53. Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990;12(suppl 3):S349-63.
54. Dismukes W, Cloud G, Thompson S, et al. Fluconazole (FLU) versus amphotericin B (AMB) therapy (Rx) of acute cryptococcal meningitis (C. M.). [abstract no 1065] In: Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1989.
55. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in acquired immunodeficiency syndrome. N Engl J Med 1991;324:580-4.
56. Powderly W, Saag M, Cloud G, et al. Fluconazole versus amphotericin B as maintenance therapy for prevention of relapse of AIDS-associated cryptococcal meningitis [abstract no 1161] In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1990.
57. Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 1989; 111:125-8.
58. Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990;69:384-91.
59. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment and review of the literature. Medicine (Baltimore) 1990;69:361-74.
60. McKinsey DS, Gupta MR, Riddler SA, Driks MR, Smith DL, Kurtin PJ. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;32:123-30.
61. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
62. EORTC International Antimicrobial Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
63. Walsh TJ, Rubin R, Hathorn J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective randomized study. Arch Intern Med 1991;151:765-70.